143 related articles for article (PubMed ID: 20501838)
1. betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer.
McCarroll JA; Gan PP; Liu M; Kavallaris M
Cancer Res; 2010 Jun; 70(12):4995-5003. PubMed ID: 20501838
[TBL] [Abstract][Full Text] [Related]
2. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.
Gan PP; Pasquier E; Kavallaris M
Cancer Res; 2007 Oct; 67(19):9356-63. PubMed ID: 17909044
[TBL] [Abstract][Full Text] [Related]
3. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
[TBL] [Abstract][Full Text] [Related]
4. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
5. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
Sève P; Reiman T; Dumontet C
Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
[TBL] [Abstract][Full Text] [Related]
6. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.
Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z
Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282
[TBL] [Abstract][Full Text] [Related]
7. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
8. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
[TBL] [Abstract][Full Text] [Related]
9. Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.
Wu YH; Cheng YW; Chang JT; Wu TC; Chen CY; Lee H
Cancer; 2007 Jul; 110(1):215-23. PubMed ID: 17508409
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
11. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide.
Yang L; Mashima T; Sato S; Mochizuki M; Sakamoto H; Yamori T; Oh-Hara T; Tsuruo T
Cancer Res; 2003 Feb; 63(4):831-7. PubMed ID: 12591734
[TBL] [Abstract][Full Text] [Related]
12. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
13. TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer.
McCarroll JA; Gan PP; Erlich RB; Liu M; Dwarte T; Sagnella SS; Akerfeldt MC; Yang L; Parker AL; Chang MH; Shum MS; Byrne FL; Kavallaris M
Cancer Res; 2015 Jan; 75(2):415-25. PubMed ID: 25414139
[TBL] [Abstract][Full Text] [Related]
14. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
15. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
Katiyar SK; Meeran SM; Katiyar N; Akhtar S
Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
[TBL] [Abstract][Full Text] [Related]
16. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
17. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
Gan PP; Kavallaris M
Cancer Res; 2008 Dec; 68(23):9817-24. PubMed ID: 19047161
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells.
Ikuta K; Takemura K; Kihara M; Nishimura M; Ueda N; Naito S; Lee E; Shimizu E; Yamauchi A
Oncol Rep; 2005 Feb; 13(2):217-22. PubMed ID: 15643501
[TBL] [Abstract][Full Text] [Related]
19. The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway.
DeCicco KL; Tanaka T; Andreola F; De Luca LM
Carcinogenesis; 2004 Oct; 25(10):1805-12. PubMed ID: 15205358
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
